Home Sports Omicron, Pfizer vaccine ready in March. Ema evaluates the pill – Foreign

Omicron, Pfizer vaccine ready in March. Ema evaluates the pill – Foreign

by admin
The production of Pfizer’s Paxlovid pill

Rome, 10 January 2022 – Covid and research: l’Mom began to evaluate an application for authorization marketing for the medicinal product antivirals orally orally Paxlovid. The question is Pfizer Europe. This was announced by the EU Agency itself. The result is expected in the coming weeks. APaxlovid is an oral antiviral medicine that “Reduces the capacity of SARS-CoV-2 (the virus that causes Covid-19) to multiply in the body ”, explains a note from Ema.

Covid: the data from Italy of 10 January

Pfizer’s application is for the treatment of mild to moderate Covid-19 in adult and adolescent patients (12 years of age and older weighing at least 40 kg) at high risk of progression to severe Covid-19. . The EMA, the note continues, “will evaluate the benefits and risks of Paxlovid in a short time and could issue an opinion within a few weeks, depending on whether the data presented are sufficiently robust or if further information is needed”.

Meanwhile, the CEO of Pfizer, Albert Bourla, stated that a vaccine for the variante Omicron of Covid it will be ready in March for marketing and that doses have already begun to be produced. “This vaccine will be ready in March,” Bourla told CNBC, adding that the vaccine will also target the other variants that are circulating.

The CEO said it is not yet clear whether or not a vaccine against Omicron is needed or how it would be used, but Pfizer will have doses available because there are governments that want it ready as soon as possible. “The hope is that we will get something that it will have better protection, particularly against infections, because protection against hospitalization and serious illness is already reasonable with current vaccines, as long as it is done the third dose“.

Read also: Basic and reinforced green pass: where it is needed

0 comment
0

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy